Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport.
about
A philosophy for CNS radiotracer designDistinct Contributions of Astrocytes and Pericytes to Neuroinflammation Identified in a 3D Human Blood-Brain Barrier on a ChipDiscovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer DiseaseSpecies differences in tumour responses to cancer chemotherapyGeneration of Brain Microvascular Endothelial-Like Cells from Human Induced Pluripotent Stem Cells by Co-Culture with C6 Glioma CellsRole of Human Breast Cancer Related Protein versus P-Glycoprotein as an Efflux Transporter for Benzylpenicillin: Potential Importance at the Blood-Brain BarrierP-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodentsChallenges of using in vitro data for modeling P-glycoprotein efflux in the blood-brain barrier.Accelerated differentiation of human induced pluripotent stem cells to blood-brain barrier endothelial cells.PET radiotracers: crossing the blood-brain barrier and surviving metabolismN-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrierImage-guided synthesis reveals potent blood-brain barrier permeable histone deacetylase inhibitors.5-HT radioligands for human brain imaging with PET and SPECTA neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomasAvoiding barriers to PET radioligand development: cellular assays of brain efflux transportersThe Effect of Exercise Training on Resting Concentrations of Peripheral Brain-Derived Neurotrophic Factor (BDNF): A Meta-Analysis.Cognition in movement disorders: where can we hope to be in ten years?Validation of a P-Glycoprotein (P-gp) Humanized Mouse Model by Integrating Selective Absolute Quantification of Human MDR1, Mouse Mdr1a and Mdr1b Protein Expressions with In Vivo Functional Analysis for Blood-Brain Barrier Transport.ABC transporter-dependent brain uptake of the 5-HT1B receptor radioligand [ (11)C]AZ10419369: a comparative PET study in mouse, rat, and guinea pigIdentification of a Cryptic Bacterial Promoter in Mouse (mdr1a) P-Glycoprotein cDNA.Differentiation and characterization of human pluripotent stem cell-derived brain microvascular endothelial cellsA potent and selective C-11 labeled PET tracer for imaging sphingosine-1-phosphate receptor 2 in the CNS demonstrates sexually dimorphic expression.Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells.Pharmacokinetic modeling of P-glycoprotein function at the rat and human blood-brain barriers studied with (R)-[11C]verapamil positron emission tomography.Modeling Ischemic Stroke In Vitro: Status Quo and Future Perspectives.Advances in PET imaging of P-glycoprotein function at the blood-brain barrier.The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects.A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PETSynthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor.Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrierOverlapping substrate and inhibitor specificity of human and murine ABCG2.Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approachHeteroaromatic and aniline derivatives of piperidines as potent ligands for vesicular acetylcholine transporter.Altered GABAA receptor density and unaltered blood-brain barrier [11C]flumazenil transport in drug-resistant epilepsy patients with mesial temporal sclerosis.Role of membrane transporters in the safety profile of drugs.Development of a physiologically-based pharmacokinetic model of the rat central nervous system.L-type calcium channels and psychiatric disorders: A brief review.Full efficacy with no CNS side-effects: unachievable panacea or reality? DMPK considerations in design of drugs with limited brain penetration.Factors influencing the use and interpretation of animal models in the development of parenteral drug delivery systems
P2860
Q26853140-67E969FB-0E41-4052-B818-B5308E3351B5Q27319805-D5E6CD40-64A6-47DE-B230-232DADBE2C75Q27674362-D75C5B01-8F48-4F13-8057-0B770F49E91DQ28080727-AE5F59F3-C824-47DE-BE26-F82D79E101A2Q28548080-5E322963-759C-4BB1-A93E-1150DB0D2F1AQ28550262-67BE0C4A-8E4E-42A2-8CBD-3824DCFEDBF4Q30544869-94CDC3D0-7A8F-4A8B-BA1D-4DBCBE7B4636Q30651426-4AD92A2E-BD39-4F1A-AAB2-1F7012B1B8FEQ33560284-8440F7D0-1B9E-4CDC-9D51-23D48D997B63Q33585028-A6E14305-75D2-40E8-BD32-622519241F19Q33891067-BB01F26C-6864-4959-8DFE-0739A107DF19Q33918201-F061155B-2207-4D5D-855B-1C3A14C2048EQ34192729-FFB3310D-AA9E-4BD2-8792-389B5F5C1EA6Q34231554-C14A3B47-5DFC-42A8-8727-6E99BFC1A609Q34285225-BBF4FD1E-D7D0-436B-98C8-223F971A4F9FQ34540937-D464E9AA-75CB-471A-91BD-91C5432CAA5AQ35211553-21F61294-9877-4DE7-9F50-8AFDD4E13F51Q35560848-DEBF86B1-1103-4942-A520-CBD15B2EF5E0Q35675506-C0B2257B-CDF2-450D-B59C-1FBAB402469AQ35756130-A7016DF4-2DB1-4AF5-8C31-21933A56D158Q35827703-E5443170-72C8-4677-B416-FA51CBC3315CQ35868052-DB1DE08D-A244-44AD-9586-F4FE365D6AE3Q36306295-DBBE2CED-2E67-4E03-B9E2-92B81717A666Q36462753-1EC8CFB7-B5C6-4B0C-88A6-99CCBD159F16Q36510263-DD352977-AB02-4C97-A96D-C46FF17E511BQ36638627-888F41F1-F733-456B-9B5D-2E02F487DF67Q36697929-D5C07A50-E4BF-453B-9979-403DA0985C99Q36949068-FA3A5CF5-1517-40FE-99F2-C3762502841EQ36949086-194B5904-6035-4472-8EAA-824750DBDBE3Q36949815-E6F8D789-28C9-4DCC-99E1-A23F7D8502EEQ36955931-4DDCF07F-B447-48B2-A1AA-5E55471FE716Q37193073-BE59721A-3C3A-41F7-B66C-C294EA957B98Q37207750-AB255279-63B9-40D6-9089-AFA970AD7766Q37244345-5D496EC9-F5C7-49B5-A298-7D7813017C5EQ37514707-FB894470-5F28-4CB5-B794-0118D95A49F5Q37575644-B518CEB6-3EFF-4C84-AAFC-CB32CFE887A2Q37689854-918B47F8-7805-4985-BA6D-0D940158AEBEQ37795701-5B9E632D-FA05-4CD5-9AA7-074F12297975Q37942267-E9DC7FB7-C6AF-4D44-A16E-0706DD0A7E24Q37942472-94BE6CF5-5495-4D5F-8AA2-98289D365478
P2860
Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport.
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Species differences in blood-b ...... s on P-glycoprotein transport.
@ast
Species differences in blood-b ...... s on P-glycoprotein transport.
@en
Species differences in blood-b ...... s on P-glycoprotein transport.
@nl
type
label
Species differences in blood-b ...... s on P-glycoprotein transport.
@ast
Species differences in blood-b ...... s on P-glycoprotein transport.
@en
Species differences in blood-b ...... s on P-glycoprotein transport.
@nl
prefLabel
Species differences in blood-b ...... s on P-glycoprotein transport.
@ast
Species differences in blood-b ...... s on P-glycoprotein transport.
@en
Species differences in blood-b ...... s on P-glycoprotein transport.
@nl
P2093
P50
P356
P1476
Species differences in blood-b ...... s on P-glycoprotein transport.
@en
P2093
Margareta Hammarlund-Udenaes
Obaidur Rahman
Orjan Lindhe
P304
P356
10.1124/DMD.108.024745
P577
2008-12-01T00:00:00Z